SecurityCDNA / CareDx, Inc. (14167L103)
IndustryMedical Laboratories
Common Shares Outstanding29,074,603 shares (as of 2017-12-31)
Total Insiders21
Total Directors7
Total Officers12

Stock Insider Trading (from SEC Form 4)

CareDx, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

CDNA / CareDx, Inc. insiders include Maag Peter, Midroc Invest AB, and DeFonzo Joshua, Nelles Mitchell J, Yee James P, LUDLUM KEN, Goldberg Michael, SNYDERMAN RALPH, Bickerstaff George, Meyer Matthew J., HAGSTROM WILLIAM A, Karlsson Anders, Whitson Todd, King Sasha Bell Michael Brian, GAGNON NEIL, Cohen Fred E, BYERS BROOK H, Sninsky John Joseph, Constanti Charles, MILLER DOUGLAS S, .

Insider Roster

Insider Dir Off 10% Shares Owned
GAGNON NEIL 10% Owner
X 2,257,064
HAGSTROM WILLIAM A Director
X 34,532
SNYDERMAN RALPH Director
X 63,799
Bickerstaff George Director
X 46,007
Goldberg Michael Director
X 126,123
Maag Peter See Remarks, Director
X X 274,037
Yee James P Chief Medical Officer
X 43,102
Nelles Mitchell J Chief Operating Officer
X 79,639
Sninsky John Joseph Chief Scientific Officer
X 22,309
Karlsson Anders Chief Commercial Officer
X 9,638
King Sasha Chief Commercial Officer
X
Bell Michael Brian Chief Financial Officer
X 14,738
Cohen Fred E Director
X
Midroc Invest AB 10% Owner
X 3,934,872
MILLER DOUGLAS S Director
X 17,695
Constanti Charles Chief Financial Officer
X
Whitson Todd Chief Commercial Officer
X
BYERS BROOK H
Meyer Matthew J. Chief Business Officer
X
DeFonzo Joshua Chief Commercial Officer
X
LUDLUM KEN Chief Financial Officer
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-04-26 4 GAGNON NEIL By Managing Member as General Partner of Gagnon Investment Associates P I 9.42 10,136 2,257,064 21,261,543
2018-04-02 4 Goldberg Michael A D 3,258 126,123
2018-04-02 4 Bickerstaff George A D 2,221 46,007
2018-04-02 4 SNYDERMAN RALPH A D 2,221 63,799
2018-04-02 4 HAGSTROM WILLIAM A A D 1,373 34,532
2018-03-27 4 Maag Peter S X D 7.869 -15,000 274,037 2,156,397
2018-03-20 4 Maag Peter M D 0.548 50,000 289,037
2018-02-14 4 Maag Peter M D 0.548 -89,938 239,037
2018-01-29 4 Maag Peter F D 6.25 -1,450 149,099
2018-01-29 4 Sninsky John Joseph F D 6.25 -805 22,309
2018-01-29 4 Nelles Mitchell J F D 6.25 -805 79,639
2018-01-29 4 Yee James P F D 6.25 -805 43,102
2018-01-19 4 Maag Peter A D 44,425 154,275
2018-01-19 4 Nelles Mitchell J A D 8,858 82,135
2018-01-19 4 Bell Michael Brian A D 14,013 14,738
2018-01-19 4 Karlsson Anders A D 9,638 9,638
2018-01-22 4 Maag Peter F D 6.29 -3,726 106,124
2018-01-22 4 Sninsky John Joseph F D 6.29 -886 23,114
2018-01-22 4 Nelles Mitchell J F D 6.29 -1,691 71,586
2018-01-22 4 Yee James P F D 6.29 -1,691 43,907
2018-01-02 4 Bickerstaff George A D 2,004 43,786
2018-01-02 4 SNYDERMAN RALPH A D 1,924 61,578
2018-01-02 4 Goldberg Michael A D 3,074 122,865
2018-01-02 4 HAGSTROM WILLIAM A A D 1,844 33,159
2017-12-08 4 Yee James P S D 7.00 -29,197 45,598 319,186
2017-12-08 4 Yee James P M D 3.3565 29,197 74,795
2017-11-30 4 Nelles Mitchell J S D 7.1691 -10,948 73,277 525,330
2017-11-30 4 Nelles Mitchell J M D 3.36 10,948 84,225
2017-10-05 4 GAGNON NEIL By self as Trustee of Gagnon Securities LLC Profit Sharing Plan P I 4.00 1,278 1,318,160 5,272,640
2017-10-05 4 GAGNON NEIL P D 4.00 9,364 2,206,399 8,825,596
2017-10-02 4 Bickerstaff George A D 5,951 41,782
2017-10-02 4 SNYDERMAN RALPH A D 5,713 59,654
2017-10-02 4 HAGSTROM WILLIAM A A D 5,475 31,315
2017-10-02 4 Goldberg Michael A D 9,125 119,791
2017-09-07 4 GAGNON NEIL By self as Trustee of Gagnon Securities LLC Profit Sharing Plan P I 3.05 856 1,316,882 4,016,490
2017-09-07 4 GAGNON NEIL P D 3.05 2,858 2,197,035 6,700,957
2017-09-07 4 GAGNON NEIL P D 3.05 2,782 2,194,177 6,692,240
2017-08-28 4 GAGNON NEIL By self as Trustee of Gagnon Securities LLC Profit Sharing Plan P I 2.77 2,410 1,316,026 3,645,392
2017-08-28 4 GAGNON NEIL P D 2.77 10,033 2,191,395 6,070,164
2017-08-28 4 GAGNON NEIL P D 2.77 9,005 2,181,362 6,042,373
2017-08-25 4 GAGNON NEIL By Managing Member as General Partner of Darwin Partnership P I 2.93 4,960 1,277,631 3,743,459
2017-08-25 4 GAGNON NEIL By self as Trustee of Gagnon Securities LLC Profit Sharing Plan P I 2.93 760 1,195,227 3,502,015
2017-08-24 4 GAGNON NEIL By Managing Member as General Partner of Darwin Partnership P I 3.19 19,577 1,272,671 4,059,820
2017-08-24 4 GAGNON NEIL By self as Trustee of Gagnon Securities LLC Profit Sharing Plan P I 2.39 1,312 1,194,467 2,854,776
2017-08-24 4 GAGNON NEIL P D 2.39 4,253 2,053,968 4,908,984
2017-08-24 4 GAGNON NEIL P D 2.39 4,257 2,049,715 4,898,819
2017-08-15 4 Maag Peter P D 1.82 350 109,850 199,927
2017-08-15 4 Maag Peter P D 1.8199 150 109,500 199,279
2017-08-15 4 Maag Peter P D 1.81 100 109,350 197,924
2017-08-15 4 Bell Michael Brian P D 1.8428 350 725 1,336
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

Related News Stories

CareDx's (CDNA) CEO Peter Maag on Q1 2018 Results - Earnings Call Transcript

2018-05-13 seekingalpha
Greetings, and welcome to the CareDx First Quarter 2018 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. (2-0)

CareDx's (CDNA) CEO Peter Maag on Q4 2017 Results - Earnings Call Transcript

2018-03-23 seekingalpha
Greetings, and welcome to the CareDx Fourth Quarter 2017 Earnings Conference Call. [Operator instructions] As a reminder, this conference is being recorded. (5-0)

Stocks To Watch: Automakers Rev Up For 2018

2017-12-31 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn on the e-mail alert on to receive this article in your inbox every Saturday morning. (629-4)

Here's Why You Should Steer Clear of LifePoint (LPNT) Stock

2017-12-12 zacks
LifePoint Health Inc.’s (LPNT - Free Report) guidance cut for third-quarter 2017 earnings and weak industry trends owing to softness in patient admission volumes have been dampening market sentiments, of late. (15-0)